<DOC>
	<DOCNO>NCT00268151</DOCNO>
	<brief_summary>The purpose study determine suitable dose Oxaliplatin safely give combination low fix dose Capecitabine limit volume radiation patient non-small cell lung cancer .</brief_summary>
	<brief_title>Oxaliplatin Combination With Capecitabine Concurrent Radiation Therapy Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The purpose study determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) Oxaliplatin combination Capecitabine radiation subject non-small cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>histologically proven nonsmall cell lung cancer inoperable Stage III A B NSCLC must measurable disease RECIST criteria one prior chemotherapy advance disease ECOG Performance Status 0 , 1 , 2 must able swallow pill work gastric feed tube evidence malabsorption negative serum betaHCG test active contraception ( female childbearing potential ) know allergy study drug willingness sign inform consent woman pregnant breastfeed ANC le 1500/mm3 platelet count le 100,000/mm3 estimate creatinine clearance le 50 cc/min ( measure CockcroftGault equation ) bilirubin le 2mg/dl SGPT great 2x nl peripheral neuropathy Grade 2 high one previous chemotherapy previous radiation therapy chest history CHF/MI significant cardiac history within last six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>XELOX-RT</keyword>
</DOC>